The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy
Abstract
Immunotherapies based on T cells have gained significant success in the treatment of diverse cancers, however, several limitations also exist, including low response, acquired resistance and severe side effects, which lead to unfavorable outcomes. Recent studies found that traditional therapies, radiotherapy and/or chemotherapy may affect the immune condition in situ and cause abscopal effect, which may improve the response of immunotherapies, enhance the efficiency, and reduce the untoward effect. Here, we review the mechanisms uncovering the cancer immunotherapy and immunogenic effects of radiotherapy and chemotherapy, aiming to highlight the principles underlying the therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy and ultimately guide better designs for future synergistic cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Case 46-1963: Ascites, Jaundice and Hepatomegaly
Stoeckle, J. D., & Scully, R. E. (1963) · New England Journal of Medicine · doi:10.1056/nejm196307112690210 · Cited by 1,502
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Whole Body Irradiation—Radiobiology or Medicine?
Mole, R. H. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-305-234 · Cited by 1,123
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling
Cai, X., Chiu, Y.-H., & Chen, Z. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.040 · Cited by 988
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Golden, E. B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J. S., Goldberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00054-6 · Cited by 667
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., Garber, J. E., Gray, R., Greenberg, C. C., Greenup, R., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0083 · Cited by 511
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Regnier, R. (1992) · PubMed · Cited by 362
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium.
Hallahan, D. E., Kuchibhotla, J., & Wyble, C. W. (1996) · PubMed · Cited by 308
Harnessing the immune system to improve cancer therapy
Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.01 · Cited by 307
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 296
進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar, L. B., Barrios, C. H., van den Bergh, J. P., et al. (2018) · Annals of Oncology · Cited by 296
Adams, S., Diamond, J. R., Hamilton, E., Pohlmann, P. R., Tolaney, S. M., Chang, C.-W., Zhang, W., Iizuka, K., Foster, P. G., Molinero, L., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5152 · Cited by 288
Brenner, D. J., & Ward, J. F. (1992) · International Journal of Radiation Biology · doi:10.1080/09553009214551591 · Cited by 274
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M. W., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0215 · Cited by 257
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 238
Ecto‐calreticulin in immunogenic chemotherapy
Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., Van Endert, P., Ghiringhelli, F., Apetoh, L., Chaput, N., Flament, C., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00567.x · Cited by 202
Brix, N., Tiefenthaller, A., Anders, H., Belka, C., & Lauber, K. (2017) · Immunological Reviews · doi:10.1111/imr.12573 · Cited by 197
Gallo, P. M., & Gallucci, S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00138 · Cited by 190
Hamano, Y., Sugimoto, H., Soubasakos, M. A., Kieran, M., Olsen, B. R., Lawler, J., Sudhakar, A., & Kalluri, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3126 · Cited by 185
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 167
Metronomic chemotherapy and immunotherapy in cancer treatment
Chen, Y.-L., Chang, M.-C., & Cheng, W.-F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.040 · Cited by 162
Angulo, I., de las Heras, F. G., Garcı́a-Bustos, J. F., Gargallo, D., Muñoz-Fernández, M. A., & Fresno, M. (2000) · Blood · doi:10.1182/blood.v95.1.212 · Cited by 161
Macrophage biology plays a central role during ionizing radiation-elicited tumor response
Wu, Q., Allouch, A., Martins, I., Modjtahedi, N., Deutsch, É., & Perfettini, J. (2017) · Biomedical Journal · doi:10.1016/j.bj.2017.06.003 · Cited by 137
Desai, S., Kumar, A., Laskar, S. S., & Pandey, B. N. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.022 · Cited by 132
Nikitina, E. Y., & Gabrilovich, D. I. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20011215)94:6<825::aid-ijc1545>3.0.co;2-5 · Cited by 131
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 126
Immuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 114
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 114
Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report
Okuma, K., Yamashita, H., Niibe, Y., Hayakawa, K., & Nakagawa, K. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-111 · Cited by 111
Cancer vaccines: Looking to the future
Yaddanapudi, K., Mitchell, R. A., & Eaton, J. W. (2013) · OncoImmunology · doi:10.4161/onci.23403 · Cited by 93
McDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R., Currie, A. J., & Robinson, B. W. S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444722 · Cited by 91
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Pandha, H., Simpson, G. R., Relph, K., Melcher, A. A., & Harrington, K. J. (2016) · Oncolytic Virotherapy · doi:10.2147/ov.s66083 · Cited by 81
Saghire, H. E., Michaux, A., Thierens, H., & Baatout, S. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1514 · Cited by 72
Pujol, J.-L., Vansteenkiste, J., Pas, T. M. D., Atanackovic, D., Reck, M., Thomeer, M., Douillard, J.-Y., Fasola, G., Potter, V. A., Taylor, P. D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000653 · Cited by 64
Rekers, N. H., Pimentel, V. O., Yaromina, A., Lieuwes, N. G., Biemans, R., Zegers, C. M. L., Germeraad, W. T. V., Limbergen, E. J. V., Neri, D., Dubois, L. J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1414119 · Cited by 52
Salem, M. L., Al-Khami, A. A., El-Naggar, S. A., Zidan, A. A., Al-Sharkawi, I. M., Diaz-Montero, C. M., & Cole, D. J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.03.010 · Cited by 51
Adapting conventional cancer treatment for immunotherapy
Qiao, J., Liu, Z., & Fu, Y. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1393-4 · Cited by 48
Adoptive Cell Therapy: Past, Present and Future
Cohen, J. E., Merims, S., Frank, S. J., Engelstein, R., Peretz, T., & Lotem, M. (2017) · Immunotherapy · doi:10.2217/imt-2016-0112 · Cited by 45
Immunological effects of chemotherapy and radiotherapy against brain tumors
Weiß, T., Weller, M., & Roth, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1229600 · Cited by 43
Raj, S. K., Bui, M. M., Springett, G. M., Conley, A. P., Lavilla-Alonso, S., Zhao, X., Chen, D., Haysek, R., Gonzalez, R. J., Letson, G. D., et al. (2015) · Sarcoma · doi:10.1155/2015/614736 · Cited by 30
Immunothérapie et radiothérapie
Bockel, S., Antoni, D., Deutsch, É., & Mornex, F. (2017) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2016.12.005 · Cited by 29
Single vs. combination immunotherapeutic strategies for glioma
Chandran, M., Candolfi, M., Shah, D., Mineharu, Y., Yadav, V. N., Koschmann, C. J., Asad, A. S., Lowenstein, P. R., & Castro, M. G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305353 · Cited by 23
Propelling Immunotherapy Combinations Into the Clinic.
Tchekmedyian, N., Gray, J. E., Creelan, B., et al. (2015) · PubMed · Cited by 20
Enhancing the Efficacy of Adoptive Cellular Therapy By Targeting Tumor-InDuced Immunosuppression
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Neeson, P. J., & Darcy, P. K. (2015) · Immunotherapy · doi:10.2217/imt.15.16 · Cited by 18
The optimism surrounding stereotactic body radiation therapy and immunomodulation
Tharmalingam, H., & Hoskin, P. (2017) · Chinese Clinical Oncology · doi:10.21037/cco.2017.05.01 · Cited by 12
Immune-related adverse events of immune checkpoint inhibitors
Tadano, H., & Torigoe, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.102 · Cited by 11
Kfoury, M., Disdero, V., Vicier, C., Saux, O. L., Gougis, P., Sajous, C., & Vignot, S. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.04.011 · Cited by 8
Cited by
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Anti-cancer peptides: classification, mechanism of action, reconstruction and modification
Xie, M., Liu, D., & Yang, Y. (2020) · Open Biology · doi:10.1098/rsob.200004 · Cited by 272
Metadata
- Authors
- Yu, W.-D., Sun, G., Li, J., Xu, J., & Wang, X.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 452
- Pages
- 66-70
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2922707684
- Cited by
- 308
- References
- 74
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.